9KUW image
Deposition Date 2024-12-04
Release Date 2025-09-17
Last Version Date 2025-09-17
Entry Detail
PDB ID:
9KUW
Title:
Cryo-EM structure of dimeric APJR and two Beta-arrestins complex with small molecules
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.49 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Beta arrestion-scFv30
Chain IDs:A, B
Chain Length:621
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Apelin receptor
Chain IDs:C (auth: Q), D (auth: R)
Chain Length:506
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Mechanistic insights into the versatile stoichiometry and biased signaling of the apelin receptor-arrestin complex.
Nat Commun 16 7403 7403 (2025)
PMID: 40790299 DOI: 10.1038/s41467-025-62870-z

Abstact

The apelin receptor (APJR) plays a pivotal role in regulating cardiovascular and metabolic health1,2. Understanding the mechanisms of biased agonism at APJR is crucial for drug discovery, as stimulation of the β-arrestin pathway may lead to some adverse effects3. Structural analyses of APJR-Gi complexes have clarified the structural basis of receptor dimerization and activation4,5, yet the absence of structural data on APJR-arrestin complexes has impeded a comprehensive understanding of APJR stoichiometry in the dual signaling pathways and biased agonism. Here, we present APJR-β-arrestin1 structures bound to a clinical drug analog, revealing 2:2 and 2:1 stoichiometries associated with differential β-arrestin recruitment. Through comparison of the two transducer-coupled APJR structures bound to the same ligand, we identify key residues and motifs crucial for directing biased signaling. These findings highlight APJR's versatile stoichiometry in coupling with β-arrestin and Gi proteins, establishing a framework for understanding biased agonism and guiding the development of therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback